Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:41:30.058Z.
Calculation as of: 2026-10-06T19:41:30.058Z.
Quote observation: 2026-10-06T19:39:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4936500bc1589ca9a686c77de910b68cd28581e4c5f82a550ef1f7d6df46dce9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$3.64M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.67M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.49M
EV/EBIT Ratio
N/A
TTM Avg
1224.32x
3Y Avg
1224.32x
5Y Avg
1224.32x
Market Cap
$3.83M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evogene Ltd. (EVGN) | $3.62M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.63M | N/A | N/A | N/A | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.64M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.67M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.55M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | 1224.32x | 1224.32x | 1224.32x |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.83M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.32M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute